Literature DB >> 23334119

Evaluation of quantitative criteria for glioma grading with static and dynamic 18F-FDopa PET/CT.

Christophe Nioche1, Marine Soret, Eric Gontier, Marion Lahutte, Guillaume Dutertre, Renaud Dulou, Laurent Capelle, Rémy Guillevin, Hervé Foehrenbach, Irène Buvat.   

Abstract

PURPOSE: The aim of this study was to compare various acquisition and processing protocols for noninvasive glioma grading using either static or dynamic (18)F-FDopa PET.
METHODS: Dynamic studies were performed in 33 patients. Based on histopathological analysis, 18 patients had a high-grade (HG) tumor and 15 patients had a low-grade (LG) tumor. For static imaging, SUV(mean) and SUV(max) were calculated for different acquisition time ranges after injection. For dynamic imaging, the transport rate constant k1 was calculated according to a compartmental kinetic analysis using an image-derived input function.
RESULTS: With the use of a 5-minute static imaging protocol starting at 38 minutes after injection, newly diagnosed HG tumors could be distinguished from LG tumors with a sensitivity of 70% and a specificity of 90% with a threshold of SUV(mean) of 2.5. In recurrent tumors, a sensitivity of 100% and a specificity of 80% for identifying HG tumors were obtained with a threshold set to 1.8. Dynamic imaging only slightly, but nonsignificantly, improved differential diagnosis.
CONCLUSIONS: Static and dynamic imaging without blood sampling can discriminate between LG and HG for both newly diagnosed and recurrent gliomas. In dynamic imaging, excellent discrimination was obtained by considering the transport rate constant k1 of tumors. In static imaging, the best discrimination based on SUV was obtained for SUV(mean) calculated from a 5-minute acquisition started at 38 minutes after injection.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23334119     DOI: 10.1097/RLU.0b013e318279fd5a

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  10 in total

Review 1.  Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas.

Authors:  Nathalie L Albert; Michael Weller; Bogdana Suchorska; Norbert Galldiks; Riccardo Soffietti; Michelle M Kim; Christian la Fougère; Whitney Pope; Ian Law; Javier Arbizu; Marc C Chamberlain; Michael Vogelbaum; Ben M Ellingson; Joerg C Tonn
Journal:  Neuro Oncol       Date:  2016-04-21       Impact factor: 12.300

2.  18F-FDOPA PET and MRI characteristics correlate with degree of malignancy and predict survival in treatment-naïve gliomas: a cross-sectional study.

Authors:  Chirag B Patel; Elisa Fazzari; Ararat Chakhoyan; Jingwen Yao; Catalina Raymond; Huytram Nguyen; Jasmine Manoukian; Nhung Nguyen; Whitney Pope; Timothy F Cloughesy; Phioanh L Nghiemphu; Johannes Czernin; Albert Lai; Benjamin M Ellingson
Journal:  J Neurooncol       Date:  2018-04-20       Impact factor: 4.130

3.  Prospective trial evaluating the sensitivity and specificity of 3,4-dihydroxy-6-[18F]-fluoro-L-phenylalanine (18F-DOPA) PET and MRI in patients with recurrent gliomas.

Authors:  Ryan S Youland; Deanna H Pafundi; Debra H Brinkmann; Val J Lowe; Jonathan M Morris; Bradley J Kemp; Christopher H Hunt; Caterina Giannini; Ian F Parney; Nadia N Laack
Journal:  J Neurooncol       Date:  2018-01-13       Impact factor: 4.130

Review 4.  Comparison of amino acid positron emission tomographic radiotracers for molecular imaging of primary and metastatic brain tumors.

Authors:  Csaba Juhász; Shalini Dwivedi; David O Kamson; Sharon K Michelhaugh; Sandeep Mittal
Journal:  Mol Imaging       Date:  2014       Impact factor: 4.488

5.  Integration of dynamic parameters in the analysis of 18F-FDopa PET imaging improves the prediction of molecular features of gliomas.

Authors:  Merwan Ginet; Timothée Zaragori; Pierre-Yves Marie; Véronique Roch; Guillaume Gauchotte; Fabien Rech; Marie Blonski; Zohra Lamiral; Luc Taillandier; Laëtitia Imbert; Antoine Verger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-09-16       Impact factor: 9.236

6.  Dynamic 18F-FDOPA-PET/MRI for the preoperative evaluation of gliomas: correlation with stereotactic histopathology.

Authors:  Maria R Ponisio; Jonathan E McConathy; Sonika M Dahiya; Michelle M Miller-Thomas; Keith M Rich; Amber Salter; Qing Wang; Pamela J LaMontagne; Gloria J Guzmán Pérez-Carrillo; Tammie L S Benzinger
Journal:  Neurooncol Pract       Date:  2020-08-07

7.  Optimization of time frame binning for FDOPA uptake quantification in glioma.

Authors:  Antoine Girard; Hervé Saint-Jalmes; Nibras Chaboub; Pierre-Jean Le Reste; Alice Metais; Anne Devillers; Florence Le Jeune; Xavier Palard-Novello
Journal:  PLoS One       Date:  2020-04-22       Impact factor: 3.240

8.  Additive Value of Dynamic FDOPA PET/CT for Glioma Grading.

Authors:  Antoine Girard; Pierre-Jean Le Reste; Alice Metais; Nibras Chaboub; Anne Devillers; Hervé Saint-Jalmes; Florence Le Jeune; Xavier Palard-Novello
Journal:  Front Med (Lausanne)       Date:  2021-07-09

9.  Pancreatic uptake and radiation dosimetry of 6-[18F]fluoro-L-DOPA from PET imaging studies in infants with congenital hyperinsulinism.

Authors:  Pradeep K Garg; Stephen J Lokitz; Lisa Truong; Burton Putegnat; Courtney Reynolds; Larry Rodriguez; Rachid Nazih; Jonathan Nedrelow; Miguel de la Guardia; John K Uffman; Sudha Garg; Paul S Thornton
Journal:  PLoS One       Date:  2017-11-08       Impact factor: 3.240

10.  Usefulness of 18F-FDOPA PET for the management of primary brain tumors: a systematic review of the literature.

Authors:  François Somme; Laura Bender; Izzie Jacques Namer; Georges Noël; Caroline Bund
Journal:  Cancer Imaging       Date:  2020-10-06       Impact factor: 3.909

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.